Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.08 USD | +2.01% | +2.63% | -31.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.96% | 2.06B | C- | ||
+33.25% | 699B | C+ | ||
+25.76% | 571B | B | ||
-3.55% | 364B | C+ | ||
+18.16% | 326B | B- | ||
+4.36% | 286B | C+ | ||
+15.52% | 236B | B+ | ||
+5.13% | 198B | B- | ||
-9.86% | 194B | A+ | ||
-3.69% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMPH Stock
- Ratings Amphastar Pharmaceuticals, Inc.